Molecular Genetics & Genomic Medicine (Oct 2022)

Risk‐reducing mastectomy decisions among women with mutations in high‐ and moderate‐ penetrance breast cancer susceptibility genes

  • Jacob G. Comeaux,
  • Julie O. Culver,
  • John E. Lee,
  • Danielle Dondanville,
  • Heather L. McArthur,
  • Emily Quinn,
  • Nicholas Gorman,
  • Charité Ricker,
  • Ming Li,
  • Caryn Lerman

DOI
https://doi.org/10.1002/mgg3.2031
Journal volume & issue
Vol. 10, no. 10
pp. n/a – n/a

Abstract

Read online

Abstract Background Women harboring mutations in breast cancer susceptibility genes are at increased lifetime risk of developing breast cancer and are faced with decisions about risk management, including whether to undergo high‐risk screening or risk‐reducing mastectomy (RRM). National guidelines recommend BRCA1 or BRCA2 mutation carriers consider RRM, but that carriers of moderate penetrance mutations (e.g., ATM or CHEK2) should be managed based on family history. We aimed to investigate determinants of decision for RRM, and hypothesized that mutation status, age, family history, partner status, and breast cancer would impact RRM decision making. Methods We performed a retrospective study assessing RRM decisions for 279 women. Results Women with BRCA and moderate penetrance gene mutations, a personal history of breast cancer, or a first degree relative with a history of breast cancer were more likely to undergo RRM. Breast cancer status and age showed an interaction effect such that women with breast cancer were less likely to undergo RRM with increasing age. Conclusion Although national guidelines do not recommend RRM for moderate penetrance carriers, the rates of RRM for this population approached those for BRCA mutation carriers. Further insights are needed to better support RRM decision‐making in this population.

Keywords